Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactideco-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies

被引:131
作者
Sanna, Vanna [1 ]
Roggio, Anna Maria [1 ]
Posadino, Anna Maria [2 ]
Cossu, Annalisa [2 ]
Marceddu, Salvatore [3 ]
Mariani, Alberto [4 ,5 ]
Alzari, Valeria [4 ,5 ]
Uzzau, Sergio [1 ,2 ]
Pintus, Gianfranco [2 ]
Sechi, Mario [6 ]
机构
[1] Porto Conte Ric, I-07041 Sassari, Italy
[2] Univ Sassari, Dept Biomed Sci, Ctr Excellence Biotechnol Dev & Biodivers Res, I-07100 Sassari, Italy
[3] CNR, Ist Sci Prod Alimentari ISPA, I-07100 Sassari, Italy
[4] Univ Sassari, Dept Chem, I-07100 Sassari, Italy
[5] Univ Sassari, Local INSTM unit, I-07100 Sassari, Italy
[6] Univ Sassari, Dipartimento Sci Farmaco, I-07100 Sassari, Italy
来源
NANOSCALE RESEARCH LETTERS | 2011年 / 6卷
关键词
DEGRADATION BEHAVIOR; PLGA NANOPARTICLES; DRUG-DELIVERY; RELEASE; MITOXANTRONE; PREDNISONE; CELLS;
D O I
10.1186/1556-276X-6-260
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Docetaxel (Dtx) chemotherapy is the optional treatment in patients with hormone-refractory metastatic prostate cancer, and Dtx-loaded polymeric nanoparticles (NPs) have the potential to induce durable clinical responses. However, alternative formulations are needed to overcome the serious side effects, also due to the adjuvant used, and to improve the clinical efficacy of the drug. In the present study, two novel biodegradable block-copolymers, poly(lactide-co-caprolactone) (PLA-PCL) and poly (lactide-co-caprolactone-co-glycolide) (PLGA-PCL), were explored for the formulation of Dtx-loaded NPs and compared with PLA- and PLGA-NPs. The nanosystems were prepared by an original nanoprecipitation method, using Pluronic F-127 as surfactant agent, and were characterized in terms of morphology, size distribution, encapsulation efficiency, crystalline structure, and in vitro release. To evaluate the potential anticancer efficacy of a nanoparticulate system, in vitro cytotoxicity studies on human prostate cancer cell line (PC3) were carried out. NPs were found to be of spherical shape with an average diameter in the range of 100 to 200 nm and a unimodal particle size distribution. Dtx was incorporated into the PLGA-PCL NPs with higher (p < 0.05) encapsulation efficiency than that of other polymers. Differential scanning calorimetry suggested that Dtx was molecularly dispersed in the polymeric matrices. In vitro drug release study showed that release profiles of Dtx varied on the bases of characteristics of polymers used for formulation. PLA-PCL and PLGA-PCL drug loaded NPs shared an overlapping release profiles, and are able to release about 90% of drug within 6 h, when compared with PLA- and PLGA-NPs. Moreover, cytotoxicity studies demonstrated advantages of the Dtx-loaded PLGA-PCL NPs over pure Dtx in both time-and concentration-dependent manner. In particular, an increase of 20% of PC3 growth inhibition was determined by PLGA-PCL NPs with respect to free drug after 72 h incubation and at all tested Dtx concentration. In summary, PLGA-PCL copolymer may be considered as an attractive and promising polymeric material for the formulation of Dtx NPs as delivery system for prostate cancer treatment, and can also be pursued as a validated system in a more large context.
引用
收藏
页数:9
相关论文
共 23 条
[11]  
Mehta Ashish K., 2007, Current Drug Delivery, V4, P185
[12]   Poloxamers and poloxamines in nanoparticle engineering and experimental medicine [J].
Moghimi, SM ;
Hunter, AC .
TRENDS IN BIOTECHNOLOGY, 2000, 18 (10) :412-420
[13]   PLA/PLGA nanoparticles for sustained release of docetaxel [J].
Musumeci, T. ;
Ventura, C. A. ;
Giannone, I. ;
Ruozi, B. ;
Montenegro, L. ;
Pignatello, R. ;
Puglisi, G. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 325 (1-2) :172-179
[14]   Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells [J].
Panyam, J ;
Labhasetwar, V .
PHARMACEUTICAL RESEARCH, 2003, 20 (02) :212-220
[15]  
Petrylak Daniel P, 2006, Rev Urol, V8 Suppl 2, pS48
[16]   Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [J].
Petrylak, DP ;
Tangen, CM ;
Hussain, MHA ;
Lara, PN,J ;
Jones, JA ;
Taplin, ME ;
Burch, PA ;
Berry, D ;
Moinpour, C ;
Kohli, M ;
Benson, MC ;
Small, EJ ;
Raghavan, D ;
Crawford, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1513-1520
[17]   Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles [J].
Reis, Catarina Pinto ;
Neufeld, Ronald J. ;
Ribeiro, Antonio J. ;
Veiga, Francisco .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2006, 2 (01) :8-21
[18]   Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake [J].
Sahoo, SK ;
Panyam, J ;
Prabha, S ;
Labhasetwar, V .
JOURNAL OF CONTROLLED RELEASE, 2002, 82 (01) :105-114
[19]   Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer [J].
Tannock, IF ;
de Wit, R ;
Berry, WR ;
Horti, J ;
Pluzanska, A ;
Chi, KN ;
Oudard, S ;
Theodore, C ;
James, ND ;
Turesson, I ;
Rosenthal, MA ;
Eisenberger, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1502-1512
[20]   The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity [J].
Yan, Fei ;
Zhang, Chao ;
Zheng, Yi ;
Mei, Lin ;
Tang, Lina ;
Song, Cunxian ;
Sun, Hongfan ;
Huang, Laiqiang .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2010, 6 (01) :170-178